EntryPoint Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

EntryPoint Capital’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,527	Closed	-$607K	–	737
2025 Q4	$607K	Buy	1,527 +469	+44%	+$208K	0.24%	106
2025 Q3	$482K	Sell	1,058 -492	-32%	-$200K	0.19%	176
2025 Q2	$505K	Sell	1,550 -814	-34%	-$225K	0.25%	95
2025 Q1	$638K	Sell	2,364 -178	-7%	-$45.7K	0.29%	38
2024 Q4	$598K	Buy	2,542 +948	+59%	+$249K	0.25%	57
2024 Q3	$438K	Buy	+1,594	New	+$415K	0.25%	93
2024 Q2	–	Sell	-1,724	Closed	-$258K	–	857
2024 Q1	$258K	Buy	1,724 +711	+70%	+$119K	0.23%	49
2023 Q4	$194K	Buy	+1,013	New	+$173K	0.19%	104

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EntryPoint Capital's ALNY Position: Q1 2026 in Review

EntryPoint Capital sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 1,527 shares — an estimated $607K sold.

EntryPoint Capital first reported a position in ALNY in Q4 2023 and held it in 8 quarters. The position peaked at $638K in Q1 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

EntryPoint Capital reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
EntryPoint Capital sold 1,527 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $607K.
EntryPoint Capital first reported a position in Alnylam Pharmaceuticals in Q4 2023 and held it in 8 quarters.
EntryPoint Capital's Alnylam Pharmaceuticals position peaked at $638K in Q1 2025.
786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.